Synthorx (THOR) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Synthorx (NASDAQ: THOR):

  • 3/19/2019 – Synthorx was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “
  • 3/18/2019 – Synthorx had its “outperform” rating reaffirmed by analysts at Svb Leerink Llc.
  • 3/16/2019 – Synthorx was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “
  • 3/15/2019 – Synthorx is now covered by analysts at Leerink Swann. They set an “outperform” rating on the stock.

Shares of THOR traded up $0.68 during midday trading on Monday, hitting $21.05. The company had a trading volume of 626 shares, compared to its average volume of 210,412. The stock has a market capitalization of $680.08 million and a PE ratio of -3.19. Synthorx Inc has a 1 year low of $11.00 and a 1 year high of $23.53.

Synthorx (NASDAQ:THOR) last announced its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.77). Research analysts forecast that Synthorx Inc will post -1.46 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of THOR. RA Capital Management LLC acquired a new stake in shares of Synthorx during the 4th quarter worth about $169,014,000. Orbimed Advisors LLC acquired a new position in Synthorx during the fourth quarter worth approximately $92,398,000. FMR LLC acquired a new position in Synthorx during the fourth quarter worth approximately $38,559,000. Matisse Capital acquired a new position in Synthorx during the fourth quarter worth approximately $956,000. Finally, Dean Capital Investments Management LLC acquired a new position in Synthorx during the fourth quarter worth approximately $827,000. 64.69% of the stock is currently owned by institutional investors and hedge funds.

Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.

See Also: Relative Strength Index

Receive News & Ratings for Synthorx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx Inc and related companies with MarketBeat.com's FREE daily email newsletter.